Status:

ACTIVE_NOT_RECRUITING

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

Lead Sponsor:

Shayna Showalter, MD

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Breast Cancer Female

Eligibility:

FEMALE

65+ years

Phase:

PHASE2

Brief Summary

This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated with 3 months of pre-op...

Detailed Description

This single arm pilot study evaluates the use of pre-operative endocrine therapy in women with early stage ER+ breast cancer who are 65 years or older and are scheduled to have breast conservation sur...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (Summary):
  • ECOG performance status 0-2
  • Diagnosed with anatomic stage I, ER positive, PR positive or negative, and HER2 non amplified invasive breast cancer and clinically negative nodes; any invasive breast cancer histologic subtype may be enrolled
  • Tumor size ≤ 2 cm
  • Patient has elected BCS as surgical choice
  • Eligible to receive tamoxifen or an aromatase inhibitor
  • Ability to take oral medication and be willing to adhere to the endocrine therapy for the 3 month period prior to BCS
  • Exclusion Criteria (Summary):
  • Prior or current use of endocrine therapy for breast cancer
  • History of ipsilateral breast radiation
  • Pregnancy or lactation
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Current or planned use of a strong CYP2D6 inhibitor (e.g. Fluoxetine, Paroxetine) and is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway

Exclusion

    Key Trial Info

    Start Date :

    April 7 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2026

    Estimated Enrollment :

    84 Patients enrolled

    Trial Details

    Trial ID

    NCT04272801

    Start Date

    April 7 2020

    End Date

    June 1 2026

    Last Update

    October 22 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    University of Virginia

    Charlottesville, Virginia, United States, 22908

    2

    Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia, United States, 23298

    Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | DecenTrialz